India, July 2 -- MacroGenics Inc. (MGNX), a clinical-stage biopharmaceutical company, on Thursday announced the prospective sale of its Good Manufacturing Practices (GMP) drug substance manufacturing facilities to Bora Pharmaceuticals.
The deal involves the transfer of the company's manufacturing site in Rockville, Maryland, the warehouse in Fredrick, Maryland, and about 140 former employees of MacroGenics over to Bora.
The purchase price is estimated to be $122.5 million.
The company also entered a supply agreement with Bora, under which Bora will support process development and drug substance production for MacroGenics' internal pipeline needs.
Moelis & Company LLC acted as financial advisor, and Sidley Austin LLP served as legal coun...